Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
17/05/2024 22:01
May 17 (Reuters) - Achilles Therapeutics PLC 698y.F :
* ACHILLES THERAPEUTICS RECEIVES NASDAQ DEFICIENCY NOTICE
REGARDING MINIMUM BID PRICE REQUIREMENT
Source text for Eikon: ID:nGNX7qlP63
Further company coverage: 698y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achilles Therapeutics
See all newsBrief: Achilles Therapeutics Announces Sale Of Technology Assets To Astrazeneca
Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement